BeiGene Q4 revenue jumps 78% to $1.13B; BRUKINSA sales double; guides FY25 $4.9-5.3B

BeOne Medicines Ltd.

2024-FY EPS reported -$0.47 vs consensus $1.19 ▼ miss (-139.4%)

Total revenue Q4 $1.13B (+78% YoY); full year $3.81B (+55% YoY).
BRUKINSA global revenue Q4 $828M (+100%); full year $2.6B (+105%).
Full year 2025 revenue guidance $4.9-$5.3B; anticipate positive GAAP operating income in 2025.
GAAP operating loss narrowed to $79M in Q4 from $384M; achieved positive non-GAAP operating income of $79M.
Advanced 6 NMEs in Q4 and 13 in full year; plan to change name to BeOne Medicines Ltd., ticker ONC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.